Exenatide extended release in patients with type 1 diabetes with and without residual insulin production
Authors:
- 23 June 2020
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (11) , 2045-2054
Abstract
Aims: To test whether a long‐acting GLP‐1 receptor agonist would improve glucose control in patients with type 1 diabetes (T1D) and to determine whether the presence of residual beta cell function would affect the response. In addition, we sought to determine whether the drug would affect beta cell function. Methods: We performed a randomized placebo‐controlled trial of exenatide extended release (ER) in participants with T1D with and without detectable levels of C‐peptide. Seventy‐nine participants were randomized to exenatide ER 2 mcg weekly, or placebo, stratified by the presence or absence of detectable C‐peptide levels. The primary outcome was the difference in glycated haemoglobin (HbA1c) levels at 24 weeks. Participants were followed for another 6 months off study drug. Results: At week 24, the time of the primary outcome, the least squares (LS) mean HbA1c level was 7.76% (95% confidence interval [CI] 7.42, 8.10) in the exenatide ER group versus 8.0% (95% CI 7.64, 8.35) in the placebo group ( P = 0.08). At week 12 the LS mean HbA1c levels were 7.71% (95% CI 7.37, 8.05) in the exenatide ER group versus 8.05% (95% CI 7.7, 8.4) in the placebo group ( P = 0.01). The improvement at week 12 was driven mainly by those with detectable levels of C‐peptide. Those treated with exenatide ER lost weight at 12 and 24 weeks compared to those treated with placebo ( P P = 0.007). The total insulin dose was lower, but not when corrected for body weight, and was not affected by residual insulin production. Adverse events were more frequent with exenatide ER, but hypoglycaemia was not increased. Conclusion: Treatment with exenatide ER may have short‐term benefits in some individuals with T1D who are overweight or who have detectable levels of C‐peptide, but short‐term improvements were not sustained.Keywords
Funding Information
- Juvenile Diabetes Research Foundation International (17‐2013‐504, 5‐ECR‐2016‐186‐A‐N)
- National Institutes of Health (P30DK02059, UL1TR000142, U01DK119083, R01DK057846, UL1TR000004, R01DK107956, P30DK036836, UL1 TR001872, P30DK045735)
This publication has 30 references indexed in Scilit:
- Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose ChallengesDiabetes Care, 2013
- Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled TrialDiabetes, 2013
- The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cellsDiabetologia, 2013
- Residual Insulin Production and Pancreatic β-Cell Turnover After 50 Years of Diabetes: Joslin Medalist StudyDiabetes, 2010
- Effects of Exenatide Alone and in Combination With Daclizumab on β-Cell Function in Long-Standing Type 1 DiabetesDiabetes Care, 2009
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 DiabetesDiabetes Care, 2004
- Analyzing incomplete longitudinal clinical trial dataBiostatistics, 2004
- Analyzing incomplete longitudinal clinical trial dataBiostatistics, 2004
- Statistical Considerations in the Intent-to-Treat PrincipleControlled Clinical Trials, 2000